For generations, the diagnosis of early-stage breast cancer has carried with it the near-certain weight of chemotherapy — a treatment as feared as the disease itself. Now, a genomic test called Prosigna is offering a different answer: for millions of patients with hormone receptor-positive, HER2-negative tumors, the data shows that hormone therapy alone is enough. A major clinical trial has confirmed what precision medicine has long promised — that knowing the genetic character of a cancer can spare a patient from treatments that were never truly necessary.
Genomic test could spare millions of breast cancer patients from chemotherapy
Millions of breast cancer patients could avoid chemotherapy-related toxicity, side effects, and quality-of-life impacts while maintaining equivalent survival outcomes.
Sometimes the best treatment is less treatment.
Mark
Why does this matter so much? Doctors have been treating breast cancer for decades. What's different now?
Mimi
The difference is precision. For a long time, doctors treated all early-stage breast cancers roughly the same way—chemotherapy plus hormone therapy, because that was the safest bet. But we now know that some of these cancers are low-risk. They respond beautifully to hormone therapy alone. The test identifies those patients.
Mark
So the test is saying: your cancer doesn't need the heavy guns?
Mimi
Exactly. And the trial proves it. Survival is the same whether you get chemo or not. So why expose someone to months of nausea, hair loss, heart damage, and cognitive problems if it won't change whether they live or die?
Mark
What about the patients who do need chemotherapy? Does the test catch them?
Mimi
Yes. It stratifies patients into risk categories. Low-risk patients skip chemo. Intermediate and high-risk patients still get it. The test is honest about who needs what.
Mark
How many people are we talking about?
Mimi
Millions. This type of breast cancer—hormone receptor-positive, HER2-negative—is the most common form. If even a fraction of those patients are low-risk, you're talking about hundreds of thousands or millions of women who could avoid chemotherapy.
Mark
What's the catch? Why isn't every oncologist using this already?
Mimi
Inertia, partly. Changing practice takes time. Guidelines need updating. Insurance companies need to cover it. And some doctors are still skeptical of genomic tests. But the evidence is strong now. That's what changes minds.
Le Pouls
- Millions of women annually face chemotherapy for early-stage breast cancer, enduring hair loss, heart damage, cognitive decline, and years of diminished quality of life — often without meaningful survival benefit.
- A landmark clinical trial has now confirmed that Prosigna's genomic risk scoring can identify low-risk patients for whom hormone therapy alone performs just as well as chemotherapy combined with hormone treatment.
- The tension lies in translation: evidence exists, but clinical guidelines, insurance coverage decisions, and oncologist habits must all shift before patients can reliably access this less-toxic path.
- The trajectory points toward a fundamental restructuring of breast cancer treatment protocols worldwide, with precision genomics moving from a supporting tool to the primary driver of clinical decisions.
For generations, the diagnosis of early-stage breast cancer has carried with it the near-certain weight of chemotherapy — a treatment as feared as the disease itself. Now, a genomic test called Prosigna is offering a different answer: for millions of patients with hormone receptor-positive, HER2-negative tumors, the data shows that hormone therapy alone is enough. A major clinical trial has confirmed what precision medicine has long promised — that knowing the genetic character of a cancer can spare a patient from treatments that were never truly necessary.
A genomic test is quietly rewriting one of oncology's most consequential decisions: who actually needs chemotherapy for early-stage breast cancer.
The test, Prosigna, developed by Veracyte, reads the genetic signature of a tumor — specifically the expression of 50 genes — and assigns it a risk score. For patients with hormone receptor-positive, HER2-negative breast cancers, a low-risk score now carries powerful new meaning. A major clinical trial has demonstrated that these patients can safely forgo chemotherapy entirely, relying on hormone therapy alone, without any compromise to their survival outcomes. The two approaches were found to be noninferior — a clinical term carrying enormous human weight.
The stakes are difficult to overstate. Chemotherapy is not merely unpleasant; it is corrosive. It strips hair, exhausts the body, clouds the mind, strains the heart, and raises the risk of secondary cancers. For decades, it was administered broadly to early-stage patients on the assumption that more aggressive treatment produced better results. That assumption has been steadily dismantled as genomic tools have matured.
What Prosigna offers is not just a test — it is a permission structure. It gives a woman facing diagnosis the data to choose a less toxic path with confidence, and it gives her oncologist the evidence to recommend it. The broader implications extend to healthcare systems spending billions managing chemotherapy's side effects.
The road from evidence to practice is rarely short. Guidelines must be revised, insurers must extend coverage, and clinicians must grow comfortable with the counterintuitive idea that less treatment can be the right treatment. But the direction is unmistakable: for millions of breast cancer patients, genomic precision is transforming a year that might have been spent in a chemotherapy chair into something else entirely.
A new genomic test is reshaping how doctors decide who needs chemotherapy for early-stage breast cancer—and the answer, for millions of patients, is nobody.
The test, called Prosigna, analyzes the genetic signature of a tumor to predict how aggressively it will behave. Veracyte, the company behind it, has long offered this kind of molecular profiling to oncologists trying to make treatment decisions. But a major clinical trial published recently provides the strongest evidence yet that for a specific group of patients—those with hormone receptor-positive, HER2-negative breast cancers—the test can identify who can safely skip chemotherapy altogether and rely on hormone therapy alone.
The stakes are enormous. Millions of women worldwide are diagnosed with this type of early-stage breast cancer each year. Chemotherapy is brutal. It causes hair loss, nausea, fatigue, and cognitive problems that can linger for years. It damages the heart and increases the risk of secondary cancers. For many patients, the psychological weight of enduring months of toxic treatment is as real as the physical toll. If a significant portion of them don't actually need it, the implications ripple across oncology.
The trial compared two approaches: patients guided by the Prosigna test who received hormone therapy alone, versus patients who received the traditional combination of chemotherapy plus hormone therapy. The results showed that hormone therapy guided by genomic testing was noninferior—meaning it performed just as well—at preventing cancer recurrence and death. Survival outcomes were equivalent. The difference was that one group avoided chemotherapy entirely.
This matters because it represents a shift toward precision medicine in breast cancer treatment. For decades, the default approach for early-stage disease was to give chemotherapy to most patients, then hope the side effects were worth it. The assumption was that more aggressive treatment meant better outcomes. But that assumption has been eroding as genomic tools have improved. Doctors now know that not all breast cancers behave the same way, and not all patients benefit equally from the same drugs.
The Prosigna test assigns tumors a risk score based on the expression of 50 genes. Low-risk tumors, the data suggests, respond well to hormone therapy alone. Intermediate and high-risk tumors may still benefit from chemotherapy. By identifying which patients fall into the low-risk category, the test allows oncologists to spare them unnecessary toxicity while still treating the cancer effectively.
The human dimension cannot be overstated. A woman diagnosed with breast cancer faces an immediate choice: trust the test and avoid chemotherapy, or choose the traditional route and endure months of treatment that may not improve her chances of survival. The test gives her data to make that choice with confidence. It also reduces the burden on healthcare systems, which spend billions on chemotherapy drugs and the management of their side effects.
What happens next will depend on how quickly this evidence translates into clinical practice. Guidelines will need to be updated. Insurance companies will need to decide whether to cover the test. Oncologists will need to become comfortable with the idea that sometimes, the best treatment is less treatment. But the direction is clear: genomic testing is moving from a tool that confirms what doctors already planned to do into a tool that fundamentally changes what they recommend. For millions of breast cancer patients, that could mean the difference between a year of their life spent in a chemotherapy chair and a year spent living it.
Citations marquantes
Survival outcomes were equivalent between hormone therapy guided by genomic testing and traditional chemotherapy plus hormone therapy— Clinical trial results
Envie de l'histoire complète ?
Lire l'original sur Google News ↗
Health & Medicine